glp-1 receptor medications Glucagon-like peptide-1 GLP-1: Genetic Variants Related to

Abstract Glucagon-like peptide-1 medicines are being prescribed to growing numbers of patients worldwide, for type 2 diabetes, obesity and associated comorbidities, including cardiovascular disease, peripheral artery disease and obstructive sleep apnea, and are revolutionizing public health strategies for these conditions

When to contact a healthcare provider While many side effects are manageable at home, some symptoms warrant reaching out for medical advice

As GLP-1 drug use expands beyond controlled trial settings and into employer-sponsored plans, Medicaid programs, and state-regulated markets, attention increasingly shifts from efficacy to accesshow many patients receive these therapies, under what conditions, and at what cost

[Google Scholar] 99

[Link] Richard N, Desprez C, Wuestenberghs F, et al